Randomized double-blind trial of intracoronary urokinase for acute myocardial infarction: multicenter study.

Abstract

The efficacy of intracoronary urokinase (UK) in an acute myocardial infarction has not been firmly established in a randomized fashion. Two hundred and ten patients were randomized to UK therapy (107 patients) and placebo (103 patients). Successful recanalization was achieved in 74% of the UK group vs 17% in the placebo group (p less than 0.01). The success rate was dose dependent up to 960,000 I.U. Clinical course was favorable and left ventricular enddiastolic pressure was reduced significantly in the UK group compared with the placebo group (p less than 0.05). Ejection fraction one month after the study was better in the reopened group than in the occluded group. Thus, early administration of UK can establish coronary reflow in a high proportion of patients and appears to favor the clinical course.

• Authors: H Kambara, K Kammatsuse, M Nobuyoshi, K Kodama, H Sato, S Sasayama, N Kajiwara, M Nakashima, C Kawai
• Journal: Japanese circulation journal (Jpn Circ J) Vol. 51 Issue 9 Pg. 1072-6 (Sep 1987) ISSN: 0047-1828 [Print] Japan
• PMID: 3320390 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Urokinase-Type Plasminogen Activator

Topics

• Aged
• Clinical Trials as Topic
• Coronary Circulation (drug effects)
• Double-Blind Method
• Drug Evaluation
• Electrocardiography
• Female
• Hemodynamics (drug effects)
• Humans
• Male
• Middle Aged
• Myocardial Infarction (drug therapy)
• Random Allocation
• Stroke Volume
• Urokinase-Type Plasminogen Activator (adverse effects, therapeutic use)